As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.

Learn more about a new study claiming that GLP-1s could be used to treat cognitive conditions like dementia, but may pose a risk to other vital organs.

A new study reveals that popular diabetes and weight loss medications like Ozempic and Wegovy may offer unexpected health benefits, from reducing addiction risk to protecting against Alzheimer’s disease.

GLP-1RA weight-loss drugs provide health benefits but also pose risks, including pancreatitis, kidney problems, and gastrointestinal issues.

A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like Ozempic and Wegovy, provide significant neurological and behavioral health benefits,

GLP-1 weight loss drugs - such as Wegovy and Mounjaro - may reduce risk of conditions including Alzheimer’s disease and dementia.

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study reporting one in eight Americans has taken or is currently using the drugs to treat diabetes,

Debate over the risks and benefits of the population weight loss drugs like Ozempic, Wegovy, and Zepbound finally came to an end after a new landmark study.According to Global News, a new observational study published in the journal

Popular GLP-1 medications for weight loss and diabetes may have unexpected benefits for reducing risks for conditions such as substance abuse, psychosis, infections and even dementia. But these drugs also come with risks that shouldn't be overlooked,

A new peer-reviewed study based on data from nearly 2M individuals highlights a wide range of clinical benefits and risks, including several newly found conditions linked to the GLP-1 class of weight loss and diabetes drugs.